☰

Andrew Flyak - Publications

Affiliations: 
2012-2016 Microbiology and Immunology Vanderbilt University School of Medicine, Nashville, TN, United States 
Tree Info Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Ogega CO, Skinner NE, Schoenle MV, Wilcox XE, Frumento N, Wright DA, Paul HT, Sinnis-Bourozikas A, Clark KE, Figueroa A, Bjorkman PJ, Ray SC, Flyak AI, Bailey JR. Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance. Immunity. PMID 38518779 DOI: 10.1016/j.immuni.2024.03.001  0.409
2023 Frumento N, Sinnis-Bourozikas A, Paul HT, Stavrakis G, Zahid MN, Wang S, Ray SC, Flyak AI, Shaw GM, Cox AL, Bailey JR. Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection. Immunity. PMID 38171362 DOI: 10.1016/j.immuni.2023.12.004  0.324
2022 Bozhanova NG, Flyak AI, Brown BP, Ruiz SE, Salas J, Rho S, Bombardi RG, Myers L, Soto C, Bailey JR, Crowe JE, Bjorkman PJ, Meiler J. Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. Nature Communications. 13: 3178. PMID 35676279 DOI: 10.1038/s41467-022-30865-9  0.428
2022 Frumento N, Figueroa A, Wang T, Zahid MN, Wang S, Massaccesi G, Stavrakis G, Crowe JE, Flyak AI, Ji H, Ray SC, Shaw G, Cox AL, Bailey JR. Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. The Journal of Clinical Investigation. PMID 35588376 DOI: 10.1172/JCI160058  0.482
2022 Ogega CO, Skinner NE, Flyak AI, Clark KE, Board NL, Bjorkman PJ, Crowe JE, Cox AL, Ray SC, Bailey JR. B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. Plos Pathogens. 18: e1010179. PMID 34990486 DOI: 10.1371/journal.ppat.1010179  0.407
2021 Weber T, Potthoff J, Bizu S, Labuhn M, Dold L, Schoofs T, Horning M, Ercanoglu MS, Kreer C, Gieselmann L, Vanshylla K, Langhans B, Janicki H, Ströh LJ, Knops E, ... ... Flyak AI, et al. Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity. PMID 34990590 DOI: 10.1016/j.immuni.2021.12.003  0.314
2021 Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, C Lorenzi JC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Da Silva J, Poston D, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. PMID 34331873 DOI: 10.1016/j.immuni.2021.07.008  0.607
2021 Murin CD, Gilchuk P, Ilinykh PA, Huang K, Kuzmina N, Shen X, Bruhn JF, Bryan AL, Davidson E, Doranz BJ, Williamson LE, Copps J, Alkutkar T, Flyak AI, Bukreyev A, et al. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Reports. 35: 108984. PMID 33852862 DOI: 10.1016/j.celrep.2021.108984  0.766
2021 Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Lorenzi JCC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Wang Z, Da Silva J, Poston D, et al. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. Biorxiv : the Preprint Server For Biology. PMID 33758864 DOI: 10.1101/2021.03.07.434227  0.586
2020 Flyak AI, Ruiz SE, Salas J, Rho S, Bailey JR, Bjorkman PJ. Author response: An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein Elife. DOI: 10.7554/Elife.53169.Sa2  0.44
2019 Kinchen VJ, Massaccesi G, Flyak AI, Mankowski MC, Colbert MD, Osburn WO, Ray SC, Cox AL, Crowe JE, Bailey JR. Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. The Journal of Clinical Investigation. 130. PMID 31408439 DOI: 10.1172/Jci130720  0.349
2019 Colbert MD, Flyak AI, Ogega CO, Kinchen VJ, Massaccesi G, Hernandez M, Davidson E, Doranz BJ, Cox AL, Crowe JE, Bailey JR. Broadly neutralizing antibodies targeting new sites of vulnerability in hepatitis C virus E1E2. Journal of Virology. PMID 31068427 DOI: 10.1128/Jvi.02070-18  0.425
2019 King LB, West BR, Moyer CL, Gilchuk P, Flyak A, Ilinykh PA, Bombardi R, Hui S, Huang K, Bukreyev A, Crowe JE, Saphire EO. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. Nature Communications. 10: 1788. PMID 30996276 DOI: 10.1038/S41467-019-09732-7  0.709
2019 Williamson L, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz B, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE. Early human B cell response to Ebola virus in four U.S. survivors of infection. Journal of Virology. PMID 30728263 DOI: 10.1128/Jvi.01439-18  0.766
2018 Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE, Bailey JR, Bjorkman PJ. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Cell Host & Microbe. 24: 703-716.e3. PMID 30439340 DOI: 10.1016/J.Chom.2018.10.009  0.348
2018 Ilinykh PA, Santos RI, Gunn BM, Kuzmina NA, Shen X, Huang K, Gilchuk P, Flyak AI, Younan P, Alter G, Crowe JE, Bukreyev A. Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap. Plos Pathogens. 14: e1007204. PMID 30138408 DOI: 10.1371/Journal.Ppat.1007204  0.639
2018 Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, Huang K, Lubaki NM, Ramanathan P, Crowe JE, Bukreyev A. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Cell Reports. 24: 1802-1815.e5. PMID 30110637 DOI: 10.1016/J.Celrep.2018.07.035  0.59
2018 Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, Bramble MS, Hoff NA, Binshtein E, Kose N, Flyak AI, et al. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity. PMID 30029854 DOI: 10.1016/J.Immuni.2018.06.018  0.793
2018 Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. The Journal of Infectious Diseases. PMID 29982718 DOI: 10.1093/Infdis/Jiy295  0.593
2018 Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, Shen X, Huang K, Ramanathan P, Turner H, Fusco ML, Lampley R, Kose N, et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nature Microbiology. PMID 29736037 DOI: 10.1038/S41564-018-0157-Z  0.792
2018 King LB, Fusco ML, Flyak AI, Ilinykh PA, Huang K, Gunn B, Kirchdoerfer RN, Hastie KM, Sangha AK, Meiler J, Alter G, Bukreyev A, Crowe JE, Saphire EO. The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. Cell Host & Microbe. 23: 101-109.e4. PMID 29324225 DOI: 10.1016/J.Chom.2017.12.003  0.748
2017 Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE, Bailey JR. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences of the United States of America. PMID 29255018 DOI: 10.1073/Pnas.1718441115  0.331
2017 Bailey JR, Flyak AI, Cohen VJ, Li H, Wasilewski LN, Snider AE, Wang S, Learn GH, Kose N, Loerinc L, Lampley R, Cox AL, Pfaff JM, Doranz BJ, Shaw GM, et al. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. Jci Insight. 2. PMID 28469084 DOI: 10.1172/Jci.Insight.92872  0.345
2017 Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Science Translational Medicine. 9. PMID 28381540 DOI: 10.1126/Scitranslmed.Aai8711  0.607
2016 Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, et al. A "Trojan horse" bispecific antibody strategy for broad protection against ebolaviruses. Science (New York, N.Y.). PMID 27608667 DOI: 10.1126/Science.Aag3267  0.647
2016 Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE, Andersen KG, Saphire EO, Ward AB. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nature Microbiology. 1: 16128. PMID 27562261 DOI: 10.1038/Nmicrobiol.2016.128  0.574
2016 Ilinykh PA, Shen X, Flyak AI, Kuzmina N, Ksiazek TG, Crowe JE, Bukreyev A. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. Journal of Virology. PMID 26819310 DOI: 10.1128/Jvi.00101-16  0.641
2016 Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, et al. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell. PMID 26806128 DOI: 10.1016/J.Cell.2015.12.022  0.803
2015 Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE, Chandran K, Saphire EO. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. Mbio. 7. PMID 26908579 DOI: 10.1128/Mbio.02154-15  0.542
2015 Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomadiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, et al. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host & Microbe. 18: 86-95. PMID 26159721 DOI: 10.1016/J.Chom.2015.06.009  0.752
2015 Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE, Saphire EO. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell. 160: 904-12. PMID 25723165 DOI: 10.1016/J.Cell.2015.01.041  0.68
2015 Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell. 160: 893-903. PMID 25723164 DOI: 10.1016/J.Cell.2015.01.031  0.779
2015 Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, et al. Erratum: Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus (Cell Host and Microbe (2015) 18 (86-95)) Cell Host & Microbe. 18. DOI: 10.1016/J.Chom.2015.08.002  0.761
2011 Nikolaiev YS, Gilchuk PV, Gorbatiuk OB, Flyak AI, Labyntsev AJ, Irodov DM, Kolibo DV, Kordium VA. Polyclonal antibodies against the human cell surface CD34 marker Cytology and Genetics. 45: 133-142. DOI: 10.3103/S0095452711030066  0.369
2009 Flyak AI, Pavlova MV, Gilchuk PV. In silico analysis of the structure of variable domains of mouse single-chain antibodies specific to the human recombinant interferon β1b Cytology and Genetics. 43: 42-47. DOI: 10.3103/S0095452709010083  0.454
Show low-probability matches.